Dr Antonio Serafin – Clinical markers for prostate cancer
Dr Antonio Serafin
- Senior Specialist Scientist, Medical Imaging and Clinical Oncology / Division of Radiobiology, University of Stellenbosch / Faculty of Medicine and Health Sciences / Tygerberg Hospital
Title of the project
Clinical markers for prostate cancer.
Prostate cancer (PCa) is the second most frequent cancer in males. Prostate cancer screening using the prostate specific antigen (PSA) is controversial due to the risk of over-diagnosis and over-treatment as most cancers diagnosed would remain asymptomatic.
Urokinase plasminogen activator (uPA) and its inhibitor type 1 (PAI-1) have been implicated in tumour aggressiveness and metastatic potential in breast cancer. In view of the relatedness of breast and prostate cancers, and similarities of the invasion process, it was decided to determine the abundance of urokinase plasminogen activator and its inhibitor in prostate tissue, using enzyme-linked immunosorbent assay (ELISA) methodology.
No definitive role of the involvement of uPA and PAI-1 in PCa has yet emerged. It also remains uncertain whether either of these two components predominates in different stages of disease to highlight a distinguishing feature which could be used for diagnosis or prognosis of PCa.